Markers of immune function and survival among cancer patients with HIV in the United States: a population-based registry linkage study

Clicks: 2
ID: 315245
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #503 of 532 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 532 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background People with HIV (PWH) and cancer have greater cancer-specific mortality than patients without HIV, which may reflect effects of immunosuppression. We aimed to describe the associations between low CD4 cell counts and cancer-specific mortality in PWH with cancer. Methods We used linked data from HIV and cancer registries to study 12 common cancers in PWH in 14 registries in the United States and Puerto Rico in 2008–2019. We used Cox regression to estimate hazard ratios (HRs) for the association of CD4 counts measured after cancer diagnosis (0–49, 50–99, 100-199, and 200+ CD4 cells/mm3) with cancer-specific mortality, adjusted for demographic and cancer-related factors. We estimated 3-year cancer-specific cumulative mortality using Fine-Gray models. Results We evaluated 12,087 PWH and cancer (the most common being non-Hodgkin lymphoma [NHL, N=2311], prostate cancer [N=1681], and Kaposi sarcoma [KS, N=1423]). Cancer-specific mortality was significantly greater for individuals with a CD4 count of 0-49 compared to 200+ cells/mm3 for NHL (HR=1.82, 95%CI=1.30–2.53), prostate cancer (HR=3.98, 95%CI=1.56–10.15), KS (HR=4.16, 95%CI=1.49–11.67), lung cancer (HR=1.69, 95%CI=1.33–2.14), colorectal cancer (HR=2.79, 95%CI=1.58–4.92), and liver cancer (HR=1.44, 95%CI=1.01–2.70). For lung cancer, those with a CD4 count of 200+ cells/mm3 had 3-year cancer-specific cumulative mortality of 52% versus 72% for those with a CD4 count of 0–49. Conclusion Among PWH with cancer, cancer-specific mortality increased with lower CD4 counts, including for solid tumors not associated with HIV, e.g., prostate and lung cancer. These results highlight the role of immunity in control of cancer.
Reference Key
openalex_W7162802170 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cameron B. Haas, Meredith S Shiels, Qianlai Luo, Ruth M Pfeiffer, Gita Suneja, Analise Monterosso, Kate Drezner, Brittani Saafir, Jennifer Hayes, Eric A Engels
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag333
URL
https://doi.org/10.1093/cid/ciag333
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.